PURPOSE: Tetraspanin CD151 is known to be involved in cancer invasion and metastasis, and its overexpression appears to be associated with a poor prognosis for various types of cancer. However, the expression status of CD151 and its prognostic impact in advanced gastric cancer (AGC) has not yet been clarified. METHODS: Immunohistochemistry was used to investigate the expression of CD151, c-erbB2, and c-Met in 159 cases of AGC. The clinicopathological and prognostic significance of these biomarkers were then evaluated. RESULTS: The overexpression of CD151 was observed in a subset of advanced gastric adenocarcinomas (25.8 %), and c-erbB2 and c-Met were overexpressed in 15.1 and 35.2 % of the cohort, respectively. CD151 overexpression was more frequently observed in tumors from younger patients (P = 0.028). There were close associations between CD151 and c-erbB2 overexpression (P = 0.033) and between c-erbB2 and c-Met overexpression (P = 0.001). CD151 overexpression was closely correlated with patient' overall survival (OS; P < 0.001) and disease-free survival (DFS; P < 0.001). Furthermore, the expression rate of CD151 seemed to increase gradually according to the depth of invasion (T stage) (χ(2) test for trend; P = 0.101), N stage (P = 0.238), and pathologic stage (P = 0.153), although trends were not statistically significant. In a multivariate analysis, CD151 overexpression was an independent prognostic factor predicting worse OS (P = 0.002) and DFS (P = 0.005), along with the T and N stage. CONCLUSIONS: CD151 was found to be an independent prognostic marker for patients with AGC.
PURPOSE: Tetraspanin CD151 is known to be involved in cancer invasion and metastasis, and its overexpression appears to be associated with a poor prognosis for various types of cancer. However, the expression status of CD151 and its prognostic impact in advanced gastric cancer (AGC) has not yet been clarified. METHODS: Immunohistochemistry was used to investigate the expression of CD151, c-erbB2, and c-Met in 159 cases of AGC. The clinicopathological and prognostic significance of these biomarkers were then evaluated. RESULTS: The overexpression of CD151 was observed in a subset of advanced gastric adenocarcinomas (25.8 %), and c-erbB2 and c-Met were overexpressed in 15.1 and 35.2 % of the cohort, respectively. CD151 overexpression was more frequently observed in tumors from younger patients (P = 0.028). There were close associations between CD151 and c-erbB2 overexpression (P = 0.033) and between c-erbB2 and c-Met overexpression (P = 0.001). CD151 overexpression was closely correlated with patient' overall survival (OS; P < 0.001) and disease-free survival (DFS; P < 0.001). Furthermore, the expression rate of CD151 seemed to increase gradually according to the depth of invasion (T stage) (χ(2) test for trend; P = 0.101), N stage (P = 0.238), and pathologic stage (P = 0.153), although trends were not statistically significant. In a multivariate analysis, CD151 overexpression was an independent prognostic factor predicting worse OS (P = 0.002) and DFS (P = 0.005), along with the T and N stage. CONCLUSIONS:CD151 was found to be an independent prognostic marker for patients with AGC.
Authors: Sang Y Ha; Jeeyun Lee; So Y Kang; In-Gu Do; Soomin Ahn; Joon O Park; Won K Kang; Min-Gew Choi; Tae S Sohn; Jae M Bae; Sung Kim; Minji Kim; Seonwoo Kim; Cheol K Park; Sai-Hong Ignatius Ou; Kyoung-Mee Kim Journal: Mod Pathol Date: 2013-06-28 Impact factor: 7.842
Authors: Pamela L Kunz; Amirkaveh Mojtahed; George A Fisher; James M Ford; Daniel T Chang; Raymond R Balise; Charles D Bangs; Athena M Cherry; Reetesh K Pai Journal: Appl Immunohistochem Mol Morphol Date: 2012-01
Authors: Kab Choong Kim; Young Wha Koh; Heung-Moon Chang; Tae Hwan Kim; Jeong Hwan Yook; Byung Sik Kim; Se Jin Jang; Young Soo Park Journal: Ann Surg Oncol Date: 2011-04-06 Impact factor: 5.344
Authors: Xiuwei H Yang; Ludmila M Flores; Qinglin Li; Pengcheng Zhou; Fenghui Xu; Ian E Krop; Martin E Hemler Journal: Cancer Res Date: 2010-03-02 Impact factor: 12.701